Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Multivariate logistic regression of the risk of requiring CKD-related pharmacotherapy during the pre-dialysis periodP valueORa (95% CI)Risk for requiring ESAs during the pre-dialysis period VDRA at referral0.0521.61 (0.99 to 2.60) Iron at referral0.0421.85 (1.02 to 3.35) eGFR at referral0.0260.95 (0.92 to 0.99) Hemoglobin ref. < 100 g/l0.0532.24 (0.99 to 4.60) Hemoglobin ref. 100- 120 g/l0.0402.18(1.28 to 3.71) iPTH ref. > 150 ng/l0.0441.66(1.01 to 2.73)Risk for requiring iron therapy during the pre-dialysis period eGFR ref. (CKD-EPI) < 0.0010.93 (0.89 to 0.97) ESAs at referral0.0582.02 (0.98 to 4.17)Risk for requiring phosphate binders during the pre-dialysis period Age > 800.030.20 (0.07 to 0.58) Age 50 to 600.090.47 (0.18 to 1.15) Age 61 to 700.080.33 (0.15 to 0.75) Age 71 to 800.020.28 (0.13 to 0.64) iPTH ref. > 150 ng/l0.032.33 (1.33 to 4.04) Hemoglobin ref. < 100 g/l0.0092.75 (1.29 to 5.86) Hemoglobin ref. 100- 120 g/l0.701.13 (0.6 to 2.09) Serum albumin > 35 g/l0.102.46 (1.29 to 5.86) eGFR ref. (CKD-EPI)0.050.93 (0.90 to 0.98)Risk for requiring VDRA during the pre-dialysis period History of diabetes0.0251.55 (1.06 to 4.77) Serum albumin > 35 g/l0.0162.40 (1.18 to 4.91) Calcium < 2.1 mmol/l0.1891.54 (0.81 to 2.93) Calcium > 2.6 mmol/l0.0402.27 (1.04 to 4.96) iPTH > 150 ng/l < 0.0013.2 (2.15 to 4.77)SESA Erythropoesis Stimulating Agent, CVD Cardiovascular disease, iPTH intact parathormone, VDRA Vitamin D receptor agonistsaOdds rations (OR) are computed through binary logistic regression.
Source: The association between phenotype, laboratory variables and medication requirements. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Identifying individuals at risk of needing CKD associated medications in a European kidney disease cohort
Study design awaiting verification · BMC Nephrology · 2024
Original publication title
Identifying individuals at risk of needing CKD associated medications in a European kidney disease cohort
© The Author(s) 2024
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
The consequences of chronic kidney disease (CKD) can be addressed with a range of pharmacotherapies primarily prescribed by nephrologists. More accurate information regarding future CKD-related pharmacotherapy requirements could guide clinical decisions including follow-up frequency.
Source: BackgroundAbstract: What methods does the paper describe?
Following assignment to derivation and validation groups (2,1), variables predicting individually future use of vitamin D receptor agonists (VDRA), phosphate binders, erythropoiesis stimulating agents (ESAs) and iron were identified using logistic regression in a prospective cohort study containing demography, comorbidity, hospitalization, laboratory, and mortality data in patients with CKD stage G4/G5 across six European countries. Discriminative ability was measured using C-statistics, and predicted probability of medication use used to inform follow-up frequency.
Source: MethodsAbstract: Results
A total of 2196 patients were included in the analysis. During a median follow-up of 735 days 648 initiated hemodialysis and 1548 did not. Combinations of age, diabetes status and iPTH, calcium, hemoglobin and serum albumin levels predicted the use of ESA, iron, phosphate binder or VDRA, with C-statistics of 0.70, 0.64, 0.73 and 0.63 in derivation cohorts respectively. Model performance in validation cohorts were similar. Sixteen percent of patients were predicted to have a likelihood of receiving any of these medications of less than 20%.
Source: ResultsAbstract: Conclusions
In a multi-country CKD cohort, prediction of ESA and phosphate binder use over a two-year period can be made based on patient characteristics with the potential to reduce frequency of follow-up in individuals with low risk for requiring these medications.
Source: ConclusionsAuthors’ abstract
Background
The consequences of chronic kidney disease (CKD) can be addressed with a range of pharmacotherapies primarily prescribed by nephrologists. More accurate information regarding future CKD-related pharmacotherapy requirements could guide clinical decisions including follow-up frequency.
Methods
Following assignment to derivation and validation groups (2,1), variables predicting individually future use of vitamin D receptor agonists (VDRA), phosphate binders, erythropoiesis stimulating agents (ESAs) and iron were identified using logistic regression in a prospective cohort study containing demography, comorbidity, hospitalization, laboratory, and mortality data in patients with CKD stage G4/G5 across six European countries. Discriminative ability was measured using C-statistics, and predicted probability of medication use used to inform follow-up frequency.
Results
A total of 2196 patients were included in the analysis. During a median follow-up of 735 days 648 initiated hemodialysis and 1548 did not. Combinations of age, diabetes status and iPTH, calcium, hemoglobin and serum albumin levels predicted the use of ESA, iron, phosphate binder or VDRA, with C-statistics of 0.70, 0.64, 0.73 and 0.63 in derivation cohorts respectively. Model performance in validation cohorts were similar. Sixteen percent of patients were predicted to have a likelihood of receiving any of these medications of less than 20%.
Conclusions
In a multi-country CKD cohort, prediction of ESA and phosphate binder use over a two-year period can be made based on patient characteristics with the potential to reduce frequency of follow-up in individuals with low risk for requiring these medications.
Supplementary Information
The online version contains supplementary material available at 10.1186/s12882-024-03497-y.
Publication and source details
Original title: Identifying individuals at risk of needing CKD associated medications in a European kidney disease cohort
Eleni Stamellou; Turgay Saritas; Marc Froissart; Florian Kronenberg; Peter Stenvinkel; David C. Wheeler; Kai-Uwe Eckardt; Jürgen Floege; James Fotheringham
BMC Nephrology · 2024
© The Author(s) 2024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.http://dx.doi.org/10.13039/501100001659Deutsche Forschungsgemeinschaft445703531Stamellou Eleni http://dx.doi.org/10.13039/501100002347Bundesministerium für Bildung und ForschungSTOP-FSGS-01GM2202CStamellou Eleni Universitätsklinikum RWTH Aachen (8915)Open Access funding enabled and organized by Projekt DEAL.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T05:07:48.340233+00:00
DOI: 10.1186/s12882-024-03497-y · PMC10880231